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Geron recently announced that it had begun enrolling patients in the world’s first-in-human clinical trial
involving cells derived from human embryonic stem cells (hESCs). This trial raises important questions
regarding the future of hESC-based therapies, especially in spinal cord injury (SCI) patients. We address
some safety and efficacy concerns with this research, as well as the ethics of fair subject selection. We
consider other populations that might be better for this research: chronic complete SCI patients for a safety
trial, subacute incomplete SCI patients for an efficacy trial, and perhaps primary progressive multiple scle-
rosis (MS) patients for a combined safety and efficacy trial.In January 2009, the U.S. Food and Drug Administration (FDA)
approved Geron’s first-in-human embryonic stem cell (hESC)
clinical trial in patients with subacute American Spinal Injury
Association (ASIA) Impairment Scale grade A thoracic spinal
cord injury (SCI) (hereafter, complete SCI) (Geron, 2009a).
Then, in August 2009, the FDA placed the trial on hold (before
any patients had been enrolled) because of concerns about the
risk of cyst formation at the injury site (Geron, 2009b). In July
2010 the clinical hold was lifted, and in October 2010 Geron
announced that it had begun to enroll patients in its Phase 1
clinical trial (Geron, 2010a).
Typically, a Phase 1 clinical trial aims ‘‘to assess the safety and
feasibility of the investigational intervention and to determine
dosages for subsequent clinical trials. Direct therapeutic benefit,
although hoped for, is unlikely in early trials, particularly if the first
participants receive low doses’’ (Lo et al., 2005). Geron’s Phase 1
clinical trial of hESC-derived oligodendrocyte progenitor cells
(GRNOPC1) involves one injection of 2 million GRNOPC1 cells
into patients within 7–14 days postinjury. The primary endpoint
for the trial is safety (‘‘as measured by the frequency and severity
of adverse events within 1 year of GRNOPC1 injection that are
related to GRNOPC1, the injection procedure used to administer
GRNOPC1, and/or the concomitant immunosuppression admin-
istered’’); however, Geron identifies efficacy as a secondary
endpoint (‘‘as measured by sensory scores and lower extremity
motor scores on International Standards for Neurological Classi-
fication of Spinal Cord Injury [ISNCSCI] examinations’’) (Geron,
2010c). This secondary endpoint is noteworthy insofar as it likely
explains the choice of subacute complete SCI patients as the
target population.
Fair subject selection is a requirement for ethical clinical
research (WMA, 2008; Emanuel et al., 2000; Levine, 1988). In
this article we critically examine this aspect of trial design and
suggest that while there are sound reasons to have chosen
subacute complete SCI patients as the target population, there
are both scientific and ethical reasons why a different patient
population—chronic complete SCI patients, subacute incom-468 Cell Stem Cell 8, May 6, 2011 ª2011 Elsevier Inc.plete SCI patients, or patients with primary progressive multiple
sclerosis (MS) with spinal lesions—might have been a more
appropriate target.
Patients with Subacute Complete SCI
Following injury, the spinal cord undergoes a cascade of
changes within hours, days, months, and years. The resulting
axonal disruption stops the bidirectional flow of information
between the brain and spinal neuronal networks beyond the
lesion site. In addition, animal models of SCI have shown that
at the level of the lesion, spared axons undergo extensive but
transient demyelination, and injured neurons undergo degenera-
tive processes that can lead to cell death.
In the last two decades, the scientific community has shown in
animal models that glial cell transplants can exhibit neuroprotec-
tive effects on the spinal cord after injury. These transplants may
spare axons and neurons that could have been harmed by SCI by
reducing the lesion size and the inflammatory reaction, by deliv-
ering trophic support, and/or by remyelinating axons in the
vicinity of the injury (for review, see Tetzlaff et al., 2010). More
recently, Keirstead and colleagues have demonstrated that
hESC-derived GRNOPC1—a type of glial cell—remyelinates
sparedaxons in addition topromoting functional recovery of fore-
limb-hindlimb coordination in a ratmodel of subacute incomplete
thoracic SCI (Cloutier et al., 2006; Keirstead et al., 2005).
Despite some concerns from the scientific community
regarding the absence of replication of the preclinical evidence
in independent laboratories and in large animal models of SCI
(e.g. cat, dog, rabbit, or primate) whose anatomy is closer to
that of human (Courtine et al., 2007; Moon and Bunge, 2005;
Kwon et al., 2010), Geron has moved forward to the first-in-
human hESC clinical trial. In a recent survey, the majority of
scientists called for independent replication as well as large
animal models to demonstrate safety and efficacy of a cell trans-
plant therapy prior to clinical translation (Kwon et al., 2010).
With the first hESC clinical trial, Geron aims to assess the
safety of hESC-derived GRNOPC1 as well as the potential of
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promote behavioral recovery in patients with subacute complete
thoracic SCI. The clinical trial is designed to replicate part of the
original study in rodents in targeting a SCI patient population at
a similar level (thoracic) and within a similar time frame
(1–2 weeks postinjury, which is referred to as a subacute period).
According to Geron, ‘‘Patients eligible for the Phase 1 trial must
have documented evidence of functionally complete SCI with
a neurological level of T3 to T10 spinal segments and agree to
have GRNOPC1 injected into the lesion sites between seven
and 14 days after injury’’ (Geron, 2010a). However, one critical
difference between the animal studies and the human trials is
the injury type. In the animal studies, the cells were tested in
rodents with incomplete SCI; in the clinical trials, the cells will
be tested in humans with complete SCI.
Patients with complete SCI with a neurological level of T3 to
T10 spinal segments exhibit a total lack of sensory, motor, and
autonomic (including bladder and bowel) functions below their
trunk and in their legs. In patients with incomplete SCI, some
neurologic function remains. In the long term, patients with SCI
are susceptible to developing medical complications such as
pressure sores, chronic pain, and respiratory, cardiovascular,
and bone problems. Successful recovery depends upon how
well these chronic conditions are ameliorated.
An Appropriate Target Population?
A significant problemwith the chosen target population, patients
with subacute complete SCI, is that the transplanted hESC-
derived GRNOPC1 (along with systemic immunosuppression)
might impair spontaneous recovery in a subset of trial partici-
pants. Six to ten percent of patients initially assessed as
complete SCI show spontaneous functional improvement over
time, suggesting the initial lesion was incomplete (Burns et al.,
2003; Consortium for Spinal Cord Medicine, 2000; Maynard
et al., 1979). Spontaneous recovery in this population (i.e.,
patients with incomplete SCI initially diagnosed as complete
SCI) might be jeopardized by participation in the GRNOPC1
trial. These patients would undergo a second surgery to
transplant the cells within 1–2 weeks after the initial SCI,
following a first operation to decompress the spinal cord and/
or stabilize the spine. In addition to the research risks of cell
transplantation and immunosuppression, this second surgery
would expose patients to additional neurosurgical risks,
including extending the lesion while transplanting the cells or
introducing infection. In this way, trial participation would disad-
vantage (some) patients relative to the standard of competent
care otherwise available to them outside the trial (Anderson
and Kimmelman, 2010).
Further, it is important to understand that patients with
subacute complete SCI are a vulnerable population. Seven to
14 days postinjury, which is the recruitment period for the Geron
trial, is a time during which the patients who will have suffered an
acute traumatic event will be experiencing stress, anxiety, fear,
and depression in degrees proportionate to the severity of injury
(Dryden et al., 2005; Illes et al., 2011; Kennedy and Rogers,
2000). These patients will have had little time to reflect on their
changed life circumstances and to fully understand and
appreciate the risks of participating in a first-in-human hESC
clinical trial. Moreover, these patients may be desperate forany opportunity to reverse their misfortune and as such may
be eager to agree to participate in research without fully under-
standing and appreciating the consequences of their decision.
The Declaration of Helsinki states:
Medical research is subject to ethical standards that
promote respect for all human subjects and protect their
health and rights. Some research populations are particu-
larly vulnerable and need special protection. These
include those who cannot give or refuse consent for them-
selves and those who may be vulnerable to coercion or
undue influence (WMA, 2008).
This is not a directive to exclude vulnerable populations from
research, but rather a call to pay particular attention to the risk
of coercion or undue influence. With this risk there is the worry
that one of the elements of free and informed choice, namely
voluntariness, will be compromised. In addition to the risk of
coercion or undue influence, there is also the risk of exploitation
(Ruof, 2004). With this risk, the concern is with the degree to
which people might be used to serve the interests of others.
With the Geron hESC-derived GRNOPC1 trial, we do not
imagine that patients with subacute complete SCI will be
coerced into research participation. We do imagine, however,
that recently diagnosed complete SCI patients—as compared
with chronic complete SCI patients or patients with primary
progressive MS with spinal lesions—may be more vulnerable
to undue influence and possibly exploitation (where exploitation
involves taking unfair advantage of another). For example, as
Miller and Rosenstein remark, ‘‘Insofar as patient-subjects
confuse research with therapy, they do not accurately compre-
hend what they are doing and thus may be vulnerable to exploi-
tation’’ (Miller and Rosenstein, 2003).
Subacute complete SCI patients are at increased risk of
conflating participating in a clinical trial with accessing novel
medical treatment(s), a phenomenon known as the therapeutic
misconception (Gilbert, 2009; Miller and Rosenstein, 2003). To
be more precise, these patients, who suddenly and unexpect-
edly find themselves in dire circumstances, may fail to
appreciate the disadvantages associated with trial participation,
where protocol design (not the needs or interests of patients)
determines what interventions patients (once they are trial
participants) will receive (Appelbaum et al., 1987; Kimmelman,
2007).
In general, first-in-human clinical trials aim to produce socially
valuable medical knowledge; they do not serve therapeutic
functions (Anderson and Kimmelman, 2010). And in particular,
Geron’s first-in-human Phase 1 hESC-derived GRNOPC1
clinical trial is about contributing to generalizable knowledge,
not about delivering cutting-edge stem cell therapy. It is doubt-
ful, however, that subacute complete SCI patients would under-
stand the invitation to enroll in Geron’s trial in these terms, unless
the consent process unambiguously explained that clinical
benefits were highly unlikely, and that ‘‘the value of the know-
ledge sought, rather than the product’s therapeutic activity’’
(Kimmelman and London, 2011) justified the move from preclin-
ical to clinical research.
Indeed, the risk of therapeutic misconception (i.e., conflat-
ing care and research) is likely to be high among patients
recently diagnosed with complete SCI who, in the immediateCell Stem Cell 8, May 6, 2011 ª2011 Elsevier Inc. 469
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clinicians than medical advice aimed at promoting their recovery
(as contrasted with advice aimed at producing medical know-
ledge to benefit society). It is our contention that, in general,
patients with subacute complete SCI are unlikely to fully under-
stand and appreciate that trial participation means the needs
and interests of science, not their personal needs and interests,
will determine the ‘‘care’’ they receive.
In addition to the therapeutic misconception, there is the
misestimation of harms and benefits. To be clear, even if
subacute complete SCI patients understand (and appreciate)
the difference between research and therapy, in the immediate
postinjury period they very likely will underestimate the potential
harms and overestimate the potential benefits of research
participation, resulting in a mistaken understanding of the
harm-benefit ratio. As Christopher Thomas Scott astutely noted,
Newly disabled persons (and the surrogates and families
who care for them) may overestimate the long-term
emotional impact of a recent injury. As a result, partici-
pants might be more likely to agree to a trial now than
they would after time passes and their expectations
change. For those living with a debilitating or deadly
disease, a person’s hope for an incremental benefit from
a safety trial—however remote—might outweigh any
considerations of risk. Restoration of bowel function for
a patient with a spinal injury represents a significant
improvement in quality of life. On the other hand, an inop-
erable tumor caused by the transplant maymean a lifetime
of peripheral pain (Scott, 2008).
Here, it is important to stress that the potential harms associ-
ated with the Geron trial are not insignificant. In addition to the
surgical risks of extending the lesion while transplanting the cells
and of infection, there are the risks of (1) preventing endogenous
remyelination, (2) promoting teratoma formation, (3) affecting
inflammation, and (4) promoting aberrant neural reorganization.
First, hESC-derived GRNOPC1 transplantation could be
hazardous in humans because GRNOPC1 transplants may be
in direct competition with endogenous progenitor-derived glial
cells. The expected benefit of GRNOPC1 resides in their poten-
tial to remyelinate axons after SCI (Cloutier et al., 2006; Keirstead
et al., 2005). Although the injured spinal cord undergoes demye-
lination of spared axons shortly following SCI, recent studies of
mouse and primate SCI have reported that axons are eventually
remyelinated by cells derived from endogenous progenitors
(Lasiene et al., 2008; Meletis et al., 2008; Sellers et al., 2009;
Yang et al., 2006). This suggests there is no chronic demyelin-
ation after SCI. In humans, the role of persistent demyelination
in neurologic dysfunction following SCI is not clear: no pro-
gressive chronic demyelination has been reported to date, and
persistent demyelination was reported in only a fraction of
patients (Guest et al., 2005; Kakulas, 1999; Norenberg et al.,
2004).
Second, there is a risk of teratoma formation generated by
undifferentiated hESCs. While differentiated stem cells
(GRNOPC1) do not seem to degenerate or migrate away from
the injection site in the rat (Cloutier et al., 2006; Coutts and
Keirstead, 2008; Keirstead et al., 2005), undifferentiated stem
cells can be harmful in nonhuman animals (Hofstetter et al.,470 Cell Stem Cell 8, May 6, 2011 ª2011 Elsevier Inc.2005) as well as in humans (Amariglio et al., 2009; Dobkin
et al., 2006). Some incidences of tumors have been reported
after transplantations of predifferentiated hESCs in the brain
(Brederlau et al., 2006; Erdo¨ et al., 2003; Roy et al., 2006). These
undifferentiated hESCs could originate from cells incompletely
differentiated before transplantation as well as from transplanted
cells that could dedifferentiate in the injured spinal cord. A few
undifferentiated stem cells might be sufficient to generate
tumors at the lesion site or at distant healthy regions of the
central nervous system. The cells could also be quiescent for
months or years before developing teratomata or teratocarci-
nomas (Knoepfler, 2009). However, it is reassuring to note that
Geron extensively investigated the number of residual undiffer-
entiated stem cells required for teratoma formation in an
immunocompromised rodent (dose response) and that no tera-
tomata were reported by Geron 12 months after GRNOPC1
transplants in the animal model (Geron, 2010b).
Third, GRNOPC1 transplants could affect the inflammation
that occurs following SCI. In animal models of SCI (Hausmann,
2003; Popovich et al., 1997; Schnell et al., 1999; Sroga et al.,
2003), neutrophils, macrophages, and microglia are believed
to contribute sequentially to inflammation that could cause
tissue damage by releasing oxidative and proteolytic enzymes
(Taoka et al., 1997), as well as proinflammatory cytokines,
reactive oxygen species, nitric oxide, and proteases (Popovich
et al., 1999, 2002). Similar inflammation has also been reported
in subacute and chronic spinal cord injuries in humans (Chang,
2007; Fleming et al., 2006; Yang et al., 2004). However, despite
extensive studies in the last 15 years, the role of inflammation
in SCI is still not understood. Indeed, both anti-inflammatory
and proinflammatory treatments have been reported to
improve recovery from SCI (for review, see Gensel et al.,
2011; Schwartz and Yoles, 2006). There are several examples
in animal models of SCI in which transplantation of adult
progenitor cells (Busch et al., 2011; Kovacsovics-Bankowski
et al., 2009) or ESCs in conjunction with immunosuppression
(Bottai et al., 2010; Hill et al., 2004) into the spinal cord has
led to a reduction in inflammation and demyelination and, in
turn, the promotion of axonal regeneration. If GRNOPC1 trans-
plants likewise reduce inflammation after SCI, this may in fact
affect recovery of function through aberrant sprouting (see
below). Furthermore, it is possible that the inflammatory
processes themselves could change the fate of transplanted
GRNOPC1 cells by differentiating and/or dedifferentiating
them. It is therefore important to determine the relationship
between hESC-derived GRNOPC1 cells and inflammation and
whether any modulation of these processes is functionally
beneficial or detrimental.
Fourth, the presence of either undifferentiated hESCs and/or
inappropriate inflammation may trigger aberrant changes to
central nervous system networks that could lead to neurologic
dysfunction, such as hyperreflexia, spasticity, dystonia, pain,
or allodynia (Dobkin et al., 2006; Hofstetter et al., 2005). For
instance, transplantation of adult neural stem cells into a rat
thoracic SCI model has been reported to improve motor
recovery, but also to cause aberrant axonal sprouting associated
with allodynia-like hypersensitivity of forepaws. Although no allo-
dynia (pain induced by normally nonnoxious stimuli) has been
reported in response to cold andmechanical stimuli in the animal
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whether abnormal neural reorganization leading to other symp-
toms and signs would occur.
To be sure, Geron has sought to minimize these potential
harms—harms that would apply with any first-in-human trial of
hESC-derived GRNOPC1, regardless of the target population.
For example, Geron screened for undifferentiated hESCs, tera-
toma formation, and potential allodynia in response to cold
and mechanical stimuli (Geron, 2010b). What is less clear is
what efforts have been made by Geron to minimize the risk
that prospective trial participants will overestimate the potential
benefits of this first-in-human trial, especially in a context where
there has been overwhelmingly positive media coverage and
endorsement from patient groups suggesting that stem cell
cures are just around the corner (Chien, 2004; Nature, 2004a;
Nature Neuroscience, 2004b; Hall, 2008; Illes et al., 2011;
Lau et al., 2008; Wade, 2005). The average person’s ability to
distinguish hype from hope is limited at the best of times and
is not likely to be particularly effective when faced with the
prospect of paralysis. This is hardly a circumstance that invites
a skeptical review of enthusiastic news reporting. Add to this
the fact that Geron’s Phase 1 trial includes secondary endpoints
that typically would be part of a Phase 2 trial, namely ‘‘improved
neuromuscular control or sensation in the trunk or lower
extremities’’ (Geron, 2010a), and patients could be forgiven for
thinking that there was a clear favorable harm-benefit ratio,
which is not the case.
An Alternative for Studying Safety:
Chronic Complete SCI Patients
The usual primary goal of a Phase 1 clinical trial is to assess
safety. Chronic complete SCI patients may be a more preferable
target population than subacute complete SCI patients in which
to assess the safety of hESC-derived GRNOPC1.
Confirmation that the lesion is complete prior to research
participation would ensure a stable environment in which to
assess the safety of hESC-derived GRNOPC1. The processes
underlying secondary injury of the spinal cord terminate after
several months (Alexander and Popovich, 2009; Steeves et al.,
2007), leading to a stable environment that may be less likely
to trigger adverse reactions. In addition, patients with chronic
injury will have had time to adjust to their life with paraplegia,
which could help diminish the risk of therapeutic misconception
and moderate the misestimation of harms and benefits. Usually,
an injury is considered chronic when patients have reached
a plateau and an improvement in function is unlikely. Typically,
this is several months after injury.
Together, these facts—stable environment in which to assess
safety, diminished risk of therapeuticmisconception, andmoder-
ated risk of misestimation of harms and benefits—suggest that
there may be fewer ethical qualms in proceeding with research
involving chronic complete SCI patients than with research
involving subacute complete SCI patients because of a more
favorable harm-benefit ratio. The reduced risk of therapeutic
misconception and therapeutic misestimation equates with
reduced potential harm to patients, and the better environment
inwhich to assess safety equateswith increasedpotential benefit
to society and theSCI community. Beyond this, if therewere ther-
apeutic benefits for chronic complete SCI patients from trialparticipation (notwithstanding preclinical findings to the
contrary), these would be clearer and more readily quantifiable,
as there would be a stable baseline neurologic status preceding
transplantation. This approach would appear to be in line with
a recently announced clinical trial by Stem Cells, Inc., in which
12 patients with chronic SCI will receive implantation of human
fetal neural cells. The study will progress from complete to
incomplete SCI populations (Globe Newswire, 2011).
An argument against conducting a ‘‘strict’’ safety trial of
GRNOPC1 in a chronic complete SCI population is that patients
with subacute complete SCI would be denied the benefits of
research participation. This argument is flawed, however, insofar
as it wrongly presumes that the cells will be proven safe and that
a first-in-human clinical trial in chronic complete SCI patients
would only serve to deny subacute complete SCI patients
access to a potentially effective stem cell intervention. Fair
subject selection is not about ensuring that everyone has the
same opportunity to expose themselves to the potential harms
of research. Rather, it is about selecting for trial participation
the least vulnerable population that can usefully answer the
research question. It is our contention that with respect to
questions about the safety and feasibility of GRNOPC1 trans-
plantation, chronic complete SCI patients are less vulnerable
than subacute complete SCI patients. Further, by proceeding
in a stepwise manner as the data warrant (from the less vulner-
able patient population to the more vulnerable patient popula-
tion), the field of stem cell research may experience fewer
setbacks in the long term in the event of unexpected, untoward
outcomes (cf. gene transfer trials [Kimmelman et al., 2006]), in
which case going more slowly at the outset could ultimately
lead more quickly to therapies proven safe and effective.
An Alternative for Studying Efficacy:
Subacute Incomplete SCI Patients
While efficacy is usually the primary goal of a Phase 2 clinical
trial, the Phase 1 Geron trial of hESC-derived GRNOPC1
includes efficacy as a secondary endpoint (Geron, 2010c).
Subacute incomplete SCI patients may be a more preferable
target population than chronic complete and subacute complete
SCI patients in which to assess the efficacy of hESC-derived
GRNOPC1.
It probably will be difficult to assess the efficacy of hESC-
derived GRNOPC1 with chronic complete SCI patients, as the
chronicity and completeness of the lesion might reduce the
statistical power of an efficacy trial. Given that 10% percent of
the complete SCI population exhibit some spontaneous func-
tional improvement (Burns et al., 2003; Consortium for Spinal
Cord Medicine, 2000; Corbetta et al., 2002; Maynard et al.,
1979), it might be expected that these are the patients with
some axons intact, and hence they may be the ones to benefit
from an early hESC-derived GRNOPC1 transplantation.
However, because of this low proportion of people expected
to show some benefit, a very large number of subacute complete
SCI patients (i.e., the patient population in the Geron study) will
be necessary to determine the degree of recovery that is
spontaneous versus GRNOPC1 mediated. On the other hand,
if effective, hESC-derived GRNOPC1 transplantation likely will
promote functional recovery only in subacute incomplete SCI
patients (Cloutier et al., 2006; Keirstead et al., 2005), presumablyCell Stem Cell 8, May 6, 2011 ª2011 Elsevier Inc. 471
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very rigid selection criteria are used to create a uniform patient
pool from which functional outcomes can be interpreted, then
the number of subacute incomplete SCI patients would be signif-
icantly smaller than that necessary if using a subacute complete
SCI population. The subacute complete and subacute incom-
plete SCI patient populations likely are equally vulnerable in
terms of the risk of undue influence and therapeutic misconcep-
tion. However, as fewer patients would be needed to reach
statistical significance in a trial involving subacute incomplete
SCI patients, ethics behooves us to select this patient popula-
tion, thereby minimizing the risk of harm over the population of
trial participants.
An Alternative for Studying Safety and Efficacy: Patients
with Primary Progressive MS with Spinal Lesions
We have recommended above two disparate patient popula-
tions for study: a chronic complete SCI population for a Phase
1 safety trial and a subacute incomplete SCI population for
a Phase 2 efficacy trial (presumably following on a prior Phase
1 trial). Geron, having an interest in studying both safety and
efficacy, has decided to proceed with a study involving
a subacute complete SCI population, thereby apparently allow-
ing the secondary goal of assessing efficacy to influence the
choice of target population for its first-in-human trial of hESC-
derived GRNOPC1. This brings us to the question: Is there
a more suitable patient population for a combined safety and
efficacy trial, if such a trial were approved by the FDA?
Geron has recently identified MS patients as a possible target
population for hESC-derived GRNOPC1 transplants, and
research in a nonhuman primate model of MS is currently
underway (Geron, 2010a). In the context of our discussion about
subject selection for the first-in-human trial of hESC-derived
GRNOPC1, it behooves us to ask the question of whether MS
patients might be a better target population for a combined
safety and efficacy study than subacute complete SCI patients.
Since GRNOPC1 remyelinate dysmyelinated and demyeli-
nated axons in several MS mouse models (Hardison et al.,
2006; Nistor et al., 2005; Totoiu et al., 2004), it is tempting to
speculate that MS patients might be a suitable population to
assess the efficacy of GRNOPC1. One treatment aimed at
improving conduction in demyelinated axons, 4-aminopyridine
(Fampridine, Acorda Therapeutics or HP184, Aventis), showed
no statistical improvements in SCI populations (Cardenas
et al., 2007; DeForge et al., 2004; van der Bruggen et al.,
2001), but led to positive functional outcomes in MS patients
(Goodman et al., 2007, 2009). As such, MS patients appear to
be more responsive than SCI patients to a pharmacologic treat-
ment targeted to demyelinated axons.
The issue with cellular therapies for MS is that the demyelin-
ation in MS is not focal, but rather affects many regions of the
central nervous system. MS can produce a wide range of
symptoms affecting sensory, motor, autonomic, and cognitive
functions. There are four main types of MS, with about 10%–
15%of patients having primary progressiveMS. This type usually
develops initially in the spinal cord, and although it may occur in
thebrain, this is usually in theabsenceof disabling cognitive func-
tion. Primary progressive MS is characterized by a steady
progression of the disease without relapses and remissions.472 Cell Stem Cell 8, May 6, 2011 ª2011 Elsevier Inc.In primary progressive MS, there is relative stability (i.e., chro-
nicity) of the symptoms, and neurological signs can be function-
ally ascribed to defined, presumably stable, spinal lesions. We
therefore ask whether patients with primary progressive MS
may be an appropriate target population for GRNOPC1 trans-
plantation. Because of the chronicity of their disease, these
patients may be less vulnerable to undue influence or exploita-
tion owing to the risks of therapeutic misconception and mises-
timation of potential harms and benefits. That is, the above
arguments supporting the enrollment of a chronic complete
SCI population for a safety trial could be extended to this primary
progressive MS population. In addition, with symptoms and
signs directly attributable to defined spinal lesions, the argu-
ments for targeting subacute incomplete SCI patients to study
efficacy would hold. However, it must be stressed that prior to
any clinical translation, research is needed to determine the
safety and efficacy of GRNOPC1 transplants in an animal model
of spinal MS such as the experimental autoimmune encephalo-
myelitis (EAE) model. If supporting data in such an animal model
are obtained, it may be reasonable to offer this population partic-
ipation in a clinical transplantation trial—had Geron so decided,
one of those trialsmight have been for hESC-derivedGRNOPC1.
Presumably this idea has occurred to Geron, since, as noted
above, it is currently doing preclinical research in a nonhuman
primate model of MS (Geron, 2010a). This raises an interesting
ethical question: If, in general terms, a primary progressive MS
patient population is less vulnerable to the risks of therapeutic
misconception and misestimation of harms and benefits than
a subacute complete SCI patient population, should Geron
have delayed its first-in-human clinical trials to gather additional
preclinical data in order to proceed with clinical research in a less
vulnerable population? This is an important question to ask and
answer, given the overriding ethical obligation to minimize the
risk of harm for trial participants.
Conclusion
In summary, the choice of a suitable population for a first-in-
human clinical trial of cell transplantation for SCI is very difficult.
Geron’s Phase 1 clinical trial of hESC-derived GRNOPC1, which
aims to assess both safety and efficacy in a subacute complete
SCI patient population, raises important scientific and ethical
questions about the choice of target population. Focusing on
safety (the usual primary endpoint of a Phase 1 trial), in conjunc-
tion with the goal of reducing avoidable risks of harm (and
thereby enhancing the harm-benefit ratio), we think that chronic
complete SCI patients would be a more suitable target popula-
tion for hESC-derived GRNOPC1 transplants than subacute
complete SCI patients. These patients are ‘‘less likely to suffer
opportunity costs from study participation’’ (Kimmelman and
London, 2011), which is an important ethical consideration
when ‘‘knowledge value,’’ not ‘‘therapeutic benefit,’’ motivates
the research. Focusing on efficacy (the usual primary endpoint
for a Phase 2 trial), in conjunction with the goal of minimizing
harm and maximizing benefit, subacute incomplete SCI patients
would be a better target population than subacute complete SCI
patients. These patients are more likely to exhibit functional
improvements and thereby potentially benefit from trial partici-
pation. Finally, if both safety and efficacy are to be studied,
then an equally good (or better) target population compared to
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progressive MS with symptoms and signs directly attributable
to specific spinal cord lesions. Primary progressive MS patients
with spinal lesions, who are refractory to current treatments,
could potentially benefit from hESC-derived GRNOPC1 trans-
plants through remyelinating their dysmyelinated spinal axons
and thus gaining neurologic functions.
As Emanuel and colleagues note, ‘‘fair subject selection
requires that the scientific goals of the study . be the primary
basis for determining the groups and individuals that will be
recruited and enrolled’’ (Emanuel et al., 2000). Persons are not
to be enrolled in clinical trials because they are ‘‘compromised
in their ability to protect themselves,’’ especially when ‘‘people
from less vulnerable groups could have met the scientific
requirements of the study’’ (Emanuel et al., 2000). Our contention
is that there are potentially less vulnerable target populations
than persons with subacute complete SCI that could have
been targeted for this research, allowing for one or both of the
stated research objectives to be realized.ACKNOWLEDGMENTS
We thank members of the NovelTechEthics research team at Dalhousie
University, Renee Hartlieb, and anonymous reviewers for helpful comments
on an earlier version of this paper. We also thank Philippe Magown for discus-
sion and comments on the design of clinical trials and Virender Bhan for
discussion about MS patients. This work was funded in part by the Canadian
Institutes of Health Research (CIHR) NNF 80045, States of Mind: Emerging
Issues in Neuroethics awarded to Franc¸oise Baylis, Canada Research Chair
in Bioethics and Philosophy. The spinal cord research of Robert Brownstone
is supported by grants from the CIHR. At the time of writing, Fre´de´ric Gilbert
was a research postdoctoral fellow on the States of Mind grant. Fre´de´ric
Bretzner is a CIHR and Paralysis Project of America (PPA) postdoctoral fellow
researcher.
REFERENCES
Alexander, J.K., and Popovich, P.G. (2009). Neuroinflammation in spinal cord
injury: therapeutic targets for neuroprotection and regeneration. Prog. Brain
Res. 175, 125–137.
Amariglio, N., Hirshberg, A., Scheithauer, B.W., Cohen, Y., Loewenthal, R.,
Trakhtenbrot, L., Paz, N., Koren-Michowitz, M., Waldman, D., Leider-Trejo,
L., et al. (2009). Donor-derived brain tumor following neural stem cell trans-
plantation in an ataxia telangiectasia patient. PLoS Med. 6, e1000029.
Anderson, J.A., and Kimmelman, J. (2010). Extending clinical equipoise to
phase 1 trials involving patients: unresolved problems. Kennedy Inst. Ethics
J. 20, 75–98.
Appelbaum, P.S., Roth, L.H., Lidz, C.W., Benson, P., andWinslade, W. (1987).
False hopes and best data: consent to research and the therapeutic miscon-
ception. Hastings Cent. Rep. 17, 20–24.
Bottai, D., Cigognini, D., Madaschi, L., Adami, R., Nicora, E., Menarini, M.,
Di Giulio, A.M., and Gorio, A. (2010). Embryonic stem cells promote motor
recovery and affect inflammatory cell infiltration in spinal cord injured mice.
Exp. Neurol. 223, 452–463.
Brederlau, A., Correia, A.S., Anisimov, S.V., Elmi, M., Paul, G., Roybon, L.,
Morizane, A., Bergquist, F., Riebe, I., Nannmark, U., et al. (2006). Transplanta-
tion of human embryonic stem cell-derived cells to a rat model of Parkinson’s
disease: effect of in vitro differentiation on graft survival and teratoma forma-
tion. Stem Cells 24, 1433–1440.
Burns, A.S., Lee, B.S., Ditunno, J.F., Jr., and Tessler, A. (2003). Patient selec-
tion for clinical trials: the reliability of the early spinal cord injury examination.
J. Neurotrauma 20, 477–482.
Busch, S.A., Hamilton, J.A., Horn, K.P., Cuascut, F.X., Cutrone, R., Lehman,
N., Deans, R.J., Ting, A.E., Mays, R.W., and Silver, J. (2011). Multipotent adultprogenitor cells prevent macrophage-mediated axonal dieback and promote
regrowth after spinal cord injury. J. Neurosci. 31, 944–953.
Cardenas, D.D., Ditunno, J., Graziani, V., Jackson, A.B., Lammertse, D.,
Potter, P., Sipski, M., Cohen, R., and Blight, A.R. (2007). Phase 2 trial of sus-
tained-release fampridine in chronic spinal cord injury. Spinal Cord 45,
158–168.
Chang, H.T. (2007). Subacute human spinal cord contusion: few lymphocytes
and many macrophages. Spinal Cord 45, 174–182.
Chien, K.R. (2004). Stem cells: lost in translation. Nature 428, 607–608.
Cloutier, F., Siegenthaler, M.M., Nistor, G., and Keirstead, H.S. (2006). Trans-
plantation of human embryonic stem cell-derived oligodendrocyte progenitors
into rat spinal cord injuries does not cause harm. Regen. Med. 1, 469–479.
Consortium for Spinal Cord Medicine. (2000). Outcomes following traumatic
spinal cord injury: clinical practice guidelines for health-care professionals.
J. Spinal Cord Med. 23, 289–316.
Corbetta, M., Burton, H., Sinclair, R.J., Conturo, T.E., Akbudak, E., and McDo-
nald, J.W. (2002). Functional reorganization and stability of somatosensory-
motor cortical topography in a tetraplegic subject with late recovery. Proc.
Natl. Acad. Sci. USA 99, 17066–17071.
Courtine, G., Bunge, M.B., Fawcett, J.W., Grossman, R.G., Kaas, J.H., Lemon,
R., Maier, I., Martin, J., Nudo, R.J., Ramon-Cueto, A., et al. (2007). Can exper-
iments in nonhuman primates expedite the translation of treatments for spinal
cord injury in humans? Nat. Med. 13, 561–566.
Coutts, M., and Keirstead, H.S. (2008). Stem cells for the treatment of spinal
cord injury. Exp. Neurol. 209, 368–377.
DeForge, D., Nymark, J., Lemaire, E., Gardner, S., Hunt, M., Martel, L., Curran,
D., and Barbeau, H. (2004). Effect of 4-aminopyridine on gait in ambulatory
spinal cord injuries: a double-blind, placebo-controlled, crossover trial. Spinal
Cord 42, 674–685.
Dobkin, B.H., Curt, A., and Guest, J. (2006). Cellular transplants in China:
observational study from the largest human experiment in chronic spinal
cord injury. Neurorehabil. Neural Repair 20, 5–13.
Dryden, D.M., Saunders, L.D., Rowe, B.H., May, L.A., Yiannakoulias, N.,
Svenson, L.W., Schopflocher, D.P., and Voaklander, D.C. (2005). Depression
following traumatic spinal cord injury. Neuroepidemiology 25, 55–61.
Emanuel, E.J., Wendler, D., and Grady, C. (2000). What makes clinical
research ethical? JAMA 283, 2701–2711.
Erdo¨, F., Bu¨hrle, C., Blunk, J., Hoehn,M., Xia, Y., Fleischmann, B., Fo¨cking,M.,
Ku¨stermann, E., Kolossov, E., Hescheler, J., et al. (2003). Host-dependent
tumorigenesis of embryonic stem cell transplantation in experimental stroke.
J. Cereb. Blood Flow Metab. 23, 780–785.
Fleming, J.C., Norenberg, M.D., Ramsay, D.A., Dekaban, G.A., Marcillo, A.E.,
Saenz, A.D., Pasquale-Styles, M., Dietrich, W.D., andWeaver, L.C. (2006). The
cellular inflammatory response in human spinal cords after injury. Brain 129,
3249–3269.
Gensel, J.C., Donnelly, D.J., and Popovich, P.G. (2011). Spinal cord injury
therapies in humans: an overview of current clinical trials and their potential
effects on intrinsic CNS macrophages. Expert Opin. Ther. Targets 15,
505–518.
Geron (2009a). Geron receives FDA clearance to begin world’s first human
clinical trial of embryonic stem cell-based therapy (http://www.geron.com/
media/pressview.aspx?id=1148).
Geron (2009b). Geron comments on FDA hold on spinal cord injury trial (http://
www.geron.com/media/pressview.aspx?id=1188).
Geron (2010a). Geron to proceed with first human clinical trial of embryonic
stem cell-based therapy (http://www.geron.com/media/pressview.aspx?
id=1229).
Geron (2010b). Preclinical Safety studies (http://www.geron.com/
GRNOPC1Trial/grnopc1-sec3.html).
Geron (2010c). Phase 1 Safety Study of GRNOPC1 in Patients with Neurolog-
ically Complete, Subacute, Spinal Cord Injury (http://clinicaltrials.gov/archive/
NCT01217008/2010_10_07).Cell Stem Cell 8, May 6, 2011 ª2011 Elsevier Inc. 473
Cell Stem Cell
PerspectiveGilbert, F. (2009). Geron’s hESC trial for spinal cord injury: the risk of thera-
peutic misconception. Bioethics Forum (http://www.thehastingscenter.org/
Bioethicsforum/Post.aspx?id=3370).
Globe Newswire (2011). Stem Cells, Inc. initiates world’s first neural stem cell
trial in spinal cord injury. MSNBC. Retrieved March 18, 2011 from http://www.
msnbc.msn.com/id/42069437.
Goodman, A.D., Cohen, J.A., Cross, A., Vollmer, T., Rizzo, M., Cohen, R.,
Marinucci, L., and Blight, A.R. (2007). Fampridine-SR in multiple sclerosis:
a randomized, double-blind, placebo-controlled, dose-ranging study. Mult.
Scler. 13, 357–368.
Goodman, A.D., Brown, T.R., Krupp, L.B., Schapiro, R.T., Schwid, S.R.,
Cohen, R., Marinucci, L.N., and Blight, A.R.; Fampridine MS-F203 Investiga-
tors. (2009). Sustained-release oral fampridine in multiple sclerosis: a rando-
mised, double-blind, controlled trial. Lancet 373, 732–738.
Guest, J.D., Hiester, E.D., and Bunge, R.P. (2005). Demyelination and
Schwann cell responses adjacent to injury epicenter cavities following chronic
human spinal cord injury. Exp. Neurol. 192, 384–393.
Hall, V.J. (2008). Embryonic stem cells and Parkinson’s disease: cell transplan-
tation to cell therapy. Ann. Acad. Med. Singapore 37, 162–163.
Hardison, J.L., Nistor, G., Gonzalez, R., Keirstead, H.S., and Lane, T.E. (2006).
Transplantation of glial-committed progenitor cells into a viral model of
multiple sclerosis induces remyelination in the absence of an attenuated
inflammatory response. Exp. Neurol. 197, 420–429.
Hausmann, O.N. (2003). Post-traumatic inflammation following spinal cord
injury. Spinal Cord 41, 369–378.
Hill, C.E., Proschel, C., Noble, M., Mayer-Proschel, M., Gensel, J.C., Beattie,
M.S., and Bresnahan, J.C. (2004). Acute transplantation of glial-restricted
precursor cells into spinal cord contusion injuries: survival, differentiation,
and effects on lesion environment and axonal regeneration. Exp. Neurol.
190, 289–310.
Hofstetter, C.P., Holmstro¨m, N.A., Lilja, J.A., Schweinhardt, P., Hao, J.,
Spenger, C., Wiesenfeld-Hallin, Z., Kurpad, S.N., Frise´n, J., and Olson, L.
(2005). Allodynia limits the usefulness of intraspinal neural stem cell grafts;
directed differentiation improves outcome. Nat. Neurosci. 8, 346–353.
Illes, J., Reimer, J.C., and Kwon, B.K. (2011). StemCell Clinical Trials for Spinal
Cord Injury: Readiness, Reluctance, Redefinition. Stem Cell Rev. Published
online April 8, 2011. 10.1007/s12015-011-9259-1.
Kakulas, B.A. (1999). The applied neuropathology of human spinal cord injury.
Spinal Cord 37, 79–88.
Keirstead, H.S., Nistor, G., Bernal, G., Totoiu, M., Cloutier, F., Sharp, K., and
Steward, O. (2005). Human embryonic stem cell-derived oligodendrocyte
progenitor cell transplants remyelinate and restore locomotion after spinal
cord injury. J. Neurosci. 25, 4694–4705.
Kennedy, P., and Rogers, B.A. (2000). Anxiety and depression after spinal cord
injury: a longitudinal analysis. Arch. Phys. Med. Rehabil. 81, 932–937.
Kimmelman, J. (2007). The therapeutic misconception at 25: treatment,
research, and confusion. Hastings Cent. Rep. 37, 36–42.
Kimmelman, J., and London, A.J. (2011). Predicting harms and benefits in
translational trials: ethics, evidence, and uncertainty. PLoS Med. 8, e1001010.
Kimmelman, J., Baylis, F., and Glass, K.C. (2006). Stem cell trials: lessons from
gene transfer research. Hastings Cent. Rep. 36, 23–26.
Knoepfler, P.S. (2009). Deconstructing stem cell tumorigenicity: a roadmap to
safe regenerative medicine. Stem Cells 27, 1050–1056.
Kovacsovics-Bankowski, M., Streeter, P.R., Mauch, K.A., Frey, M.R., Raber,
A., van’t Hof, W., Deans, R., and Maziarz, R.T. (2009). Clinical scale expanded
adult pluripotent stem cells prevent graft-versus-host disease. Cell. Immunol.
255, 55–60.
Kwon, B.K., Hillyer, J., and Tetzlaff, W. (2010). Translational research in spinal
cord injury: a survey of opinion from the SCI community. J. Neurotrauma 27,
21–33.
Lasiene, J., Shupe, L., Perlmutter, S., and Horner, P. (2008). No evidence for
chronic demyelination in spared axons after spinal cord injury in a mouse.
J. Neurosci. 28, 3887–3896.474 Cell Stem Cell 8, May 6, 2011 ª2011 Elsevier Inc.Lau, D., Ogbogu, U., Taylor, B., Stafinski, T., Menon, D., and Caulfield, T.
(2008). Stem cell clinics online: the direct-to-consumer portrayal of stem cell
medicine. Cell Stem Cell 3, 591–594.
Levine, R.J. (1988). Ethics and Regulations of Clinical Research, Second
Edition (New Haven, Connecticut: Yale University Press).
Lo, B., Zettler, P., Cedars, M.I., Gates, E., Kriegstein, A.R., Oberman, M., Reijo
Pera, R., Wagner, R.M., Wuerth, M.T., Wolf, L.E., and Yamamoto, K.R. (2005).
A new era in the ethics of human embryonic stem cell research. Stem Cells 23,
1454–1459.
Maynard, F.M., Reynolds, G.G., Fountain, S., Wilmot, C., and Hamilton, R.
(1979). Neurological prognosis after traumatic quadriplegia. Three-year expe-
rience of California Regional Spinal Cord Injury Care System. J. Neurosurg. 50,
611–616.
Meletis, K., Barnabe´-Heider, F., Carle´n, M., Evergren, E., Tomilin, N., Shuplia-
kov, O., and Frise´n, J. (2008). Spinal cord injury reveals multilineage differen-
tiation of ependymal cells. PLoS Biol. 6, e182.
Miller, F.G., and Rosenstein, D.L. (2003). The therapeutic orientation to clinical
trials. N. Engl. J. Med. 348, 1383–1386.
Moon, L., and Bunge, M.B. (2005). From animal models to humans: strategies
for promoting CNS axon regeneration and recovery of limb function after spinal
cord injury. J. Neurol. Phys. Ther. 29, 55–69.
Nature. (2004a). No consensus on stem cells. Nature 428, 587.
Nature Neuroscience. (2004b). The promise of stem cells. Nat. Neurosci. 7,
1013.
Nistor, G.I., Totoiu, M.O., Haque, N., Carpenter, M.K., and Keirstead, H.S.
(2005). Human embryonic stem cells differentiate into oligodendrocytes in
high purity and myelinate after spinal cord transplantation. Glia 49, 385–396.
Norenberg, M.D., Smith, J., and Marcillo, A. (2004). The pathology of human
spinal cord injury: defining the problems. J. Neurotrauma 21, 429–440.
Popovich, P.G., Wei, P., and Stokes, B.T. (1997). Cellular inflammatory
response after spinal cord injury in Sprague-Dawley and Lewis rats.
J. Comp. Neurol. 377, 443–464.
Popovich, P.G., Guan, Z., Wei, P., Huitinga, I., van Rooijen, N., and Stokes,
B.T. (1999). Depletion of hematogenous macrophages promotes partial hind-
limb recovery and neuroanatomical repair after experimental spinal cord injury.
Exp. Neurol. 158, 351–365.
Popovich, P.G., Guan, Z., McGaughy, V., Fisher, L., Hickey, W.F., and Basso,
D.M. (2002). The neuropathological and behavioral consequences of intra-
spinal microglial/macrophage activation. J. Neuropathol. Exp. Neurol. 61,
623–633.
Roy, N.S., Cleren, C., Singh, S.K., Yang, L., Beal, M.F., and Goldman, S.A.
(2006). Functional engraftment of human ES cell-derived dopaminergic
neurons enriched by coculture with telomerase-immortalized midbrain astro-
cytes. Nat. Med. 12, 1259–1268.
Ruof, M.C. (2004). Vulnerability, vulnerable populations, and policy. Kennedy
Inst. Ethics J. 14, 411–425.
Schnell, L., Fearn, S., Klassen, H., Schwab, M.E., and Perry, V.H. (1999). Acute
inflammatory responses to mechanical lesions in the CNS: differences
between brain and spinal cord. Eur. J. Neurosci. 11, 3648–3658.
Schwartz, M., and Yoles, E. (2006). Immune-based therapy for spinal cord
repair: autologous macrophages and beyond. J. Neurotrauma 23, 360–370.
Scott, C.T. (2008). Stem cells: new frontiers of ethics, law, and policy. Neuro-
surg. Focus 24, E24.
Sellers, D.L., Maris, D.O., and Horner, P.J. (2009). Postinjury niches induce
temporal shifts in progenitor fates to direct lesion repair after spinal cord injury.
J. Neurosci. 29, 6722–6733.
Sroga, J.M., Jones, T.B., Kigerl, K.A., McGaughy, V.M., and Popovich, P.G.
(2003). Rats and mice exhibit distinct inflammatory reactions after spinal
cord injury. J. Comp. Neurol. 462, 223–240.
Steeves, J.D., Lammertse, D., Curt, A., Fawcett, J.W., Tuszynski, M.H.,
Ditunno, J.F., Ellaway, P.H., Fehlings, M.G., Guest, J.D., Kleitman, N., et al;
International Campaign for Cures of Spinal Cord Injury Paralysis. (2007).
Cell Stem Cell
PerspectiveGuidelines for the conduct of clinical trials for spinal cord injury (SCI) as devel-
oped by the ICCP panel: clinical trial outcome measures. Spinal Cord 45,
206–221.Taoka, Y., Okajima, K., Uchiba, M., Murakami, K., Kushimoto, S., Johno, M.,
Naruo, M., Okabe, H., and Takatsuki, K. (1997). Role of neutrophils in spinal
cord injury in the rat. Neuroscience 79, 1177–1182.Tetzlaff, W., Okon, E.B., Karimi-Abdolrezaee, S., Hill, C.E., Sparling, J.S.,
Plemel, J.R., Plunet, W.T., Tsai, E.C., Baptiste, D., Smithson, L.J., et al.
(2010). A Systematic Review of Cellular Transplantation Therapies for Spinal
Cord Injury. J. Neurotrauma. Published online April 20, 2010. 10.1089/neu.
2009.1177.Totoiu, M.O., Nistor, G.I., Lane, T.E., and Keirstead, H.S. (2004). Remyelina-
tion, axonal sparing, and locomotor recovery following transplantation of
glial-committed progenitor cells into the MHV model of multiple sclerosis.
Exp. Neurol. 187, 254–265.van der Bruggen, M.A., Huisman, H.B., Beckerman, H., Bertelsmann, F.W.,
Polman, C.H., and Lankhorst, G.J. (2001). Randomized trial of 4-aminopyridine
in patients with chronic incomplete spinal cord injury. J. Neurol. 248, 665–671.
Wade, N. (2005). Tracking the Uncertain Science of Growing Heart Cells. New
York Times. Retrieved April 22, 2011 from http://www.nytimes.com/2005/03/
14/health/14heart.html.
World Medical Association (WMA) (2008). WMA Declaration of Helsinki -
Ethical Principles for Medical Research Involving Human Subjects (http://
www.wma.net/en/30publications/10policies/b3/index.html).
Yang, L., Blumbergs, P.C., Jones, N.R., Manavis, J., Sarvestani, G.T., and
Ghabriel, M.N. (2004). Early expression and cellular localization of proinflam-
matory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-
alpha in human traumatic spinal cord injury. Spine 29, 966–971.
Yang, H., Lu, P., McKay, H.M., Bernot, T., Keirstead, H., Steward, O., Gage,
F.H., Edgerton, V.R., and Tuszynski, M.H. (2006). Endogenous neurogenesis
replaces oligodendrocytes and astrocytes after primate spinal cord injury.
J. Neurosci. 26, 2157–2166.Cell Stem Cell 8, May 6, 2011 ª2011 Elsevier Inc. 475
